NCT01976169: Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

NCT01976169
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 90 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with Rb+ tumors, Patients with known active CNS metastases that require steroids
https://ClinicalTrials.gov/show/NCT01976169

Comments are closed.

Up ↑